The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

Published:2015-02-27 Issue:5 Volume:90 Page:E86-E91
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Harrison Simon J.¹²,Quach Hang³,Link Emma¹,Feng Huaibao⁴,Dean Joanne¹,Copeman Michael⁵,Van De Velde Helgi⁶,Schwarer Anthony⁷,Baker Bartrum⁸,Spencer Andrew⁹,Catalano John¹⁰,Campbell Philip¹¹,Augustson Bradley¹²,Romeril Ken¹³,Prince Henry Miles¹²

Affiliation:

1. Peter MacCallum Cancer Centre; East Melbourne Australia

2. Sir Peter MacCallum Department of Oncology; University of Melbourne; Parkville Australia

3. St Vincents Hospital; Melbourne Australia

4. Janssen Research & Development; Raritan, New Jersey

5. Janssen-Cilag Pty Ltd; Sydney Australia

6. Janssen Research & Development; Beerse Belgium

7. Box Hill Hospital; Melbourne Australia

8. Palmerston North Hospital; Palmerston North New Zealand

9. the Alfred Hospital; Melbourne Australia

10. Frankston Hospital; Melbourne Australia

11. The Andrew Love Cancer Centre; Geelong Hospital; Geelong Australia

12. Sir Charles Gairdner Hospital; Perth Australia

13. Wellington Hospital; Wellington New Zealand

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23967/fullpdf

Reference33 articles.

1. Recent major improvement in long-term survival of younger patients with multiple myeloma;Brenner;Blood,2008

2. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

3. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma;Kikuchi;Blood,2010

4. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model;LeBlanc;Cancer Res,2002

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNA Therapeutics for Cancers;RNA Therapeutics - History, Design, Manufacturing, and Applications [Working Title];2022-09-16

2. A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma;Critical Reviews in Oncology/Hematology;2018-01

3. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?;Critical Reviews in Oncology/Hematology;2017-04

4. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study;Leukemia;2017-01-11

5. Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma;British Journal of Haematology;2016-12-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3